Edition:
United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

1.52USD
1:33pm EST
Change (% chg)

$0.08 (+5.17%)
Prev Close
$1.45
Open
$1.65
Day's High
$1.65
Day's Low
$1.50
Volume
7,327
Avg. Vol
18,929
52-wk High
$3.37
52-wk Low
$1.10

CGIX.OQ

Chart for CGIX.OQ

About

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personaliz... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $27.39
Shares Outstanding(Mil.): 18.89
Dividend: --
Yield (%): --

Financials

  CGIX.OQ Industry Sector
P/E (TTM): -- 38.38 30.77
EPS (TTM): -1.37 -- --
ROI: -57.95 8.91 15.23
ROE: -74.72 12.46 16.56

BRIEF-Cancer Genetics Q3 loss per share $0.23

* Q3 revenue $6.8 million Source text for Eikon: Further company coverage:

Nov 10 2016

BRIEF-Cancer Genetics announces global partnership with BARC global central laboratory

* Cancer Genetics, Inc. announces a global partnership with BARC global central laboratory to offer comprehensive clinical trial and companion diagnostic solutions for the oncology industry Source text for Eikon: Further company coverage:

Sep 20 2016

BRIEF-Cancer Genetics announces $5.5 mln registered direct offering

* Cancer genetics announces $5.5 million registered direct offering

Sep 09 2016

BRIEF-Cancer Genetics receives New York state approval for Focus::Myeloid NGS-based panel

* Received New York state approval for its Focus::Myeloid NGS-based panel for Myeloid malignancies Source text for Eikon: Further company coverage:

Aug 17 2016

BRIEF-Cancer Genetics says gets NY state approval for Focus:CLL panel

* Says received New York state approval for its Focus::CLL panel Source text for Eikon: Further company coverage:

Jun 30 2016

BRIEF-Cancer Genetics names John Jay roberts as COO and executive VP of finance

* Cancer genetics names healthcare technology industry veteran john Jay Roberts as COO and executive vice president of finance Source text for Eikon: Further company coverage:

Jun 27 2016

Competitors

Earnings vs. Estimates